Miltefosine Plus IL Pentamidine for Bolivian CL

Miltefosine Combined With Intralesional Pentamidine for Leishmania Braziliensis Cutaneous Leishmaniasis in Bolivia

Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).

Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5). Efficacy and tolerance parameters were assessed. Efficacy was assessed at 1, 3, and 6 months post therapy. Tolerance was assessed on each day therapy was administered.

Inclusion Criteria:

• one ulcerative lesion ≤ 900 mm2 in total area,
• ≥ 12 years,
• parasitologically diagnosed by visualization of amastigotes or culture of promastigotes from lesion material,
• no antileishmanial therapy in the last 3 months,
• no mucosal lesions,
• no history of significant concomitant diseases including immunosuppression.

Exclusion Criteria: